HIP-15: Topical TRH as a Non-Drug Hair Growth-Stimulatory Agent

Attention HairForce ! I am hereby proposing the second collaboration between HairDAO and Cutaneon, who also developed our T34 treatment. The brief concept is to develop a hair follicle-targeting vehicle that delivers a therapeutically effective dose of thyrotropin-releasing hormone (TRH) in order to stimulate hair growth and/or reduce hair loss.

TRH is expected to be synergistic with our existing Thyroid Hormone treatment as it operates within the same hypothalamus-pituitary-thyroid axis yet it operates via a completely different mechanism of action. Thus, we believe TRH will be additive to our Thyroid Hormone Treatment.

The terms of the agreement with Cutaneon are as follows:

Cutaneon receives 256.5 K € for one year of research

• 135K € payable upon contract signature
• 40.5K* € payable after Milestone 1 Interim Report
• 40.5K € payable after Milestone 2 Interim Report
• 40.5K € payable after receipt of Final Report

HairDAO owns 95% of the IP generated by the study

• HairDAO has the option to purchase the remaining 5% of the IP from Cutaneon with a 10x cap on valuation.

For additional information on the concept and strategy behind this study, please read the document linked below and/or watch the episode of the Hairy Matters podcast linked below:

• https://drive.google.com/file/d/1c3Li3fPW-ZOzKoD1TqJTjHDFetCttlpC/view?usp=sharing
• https://www.youtube.com/watch?v=awP4fTtBxKM&t=1585s